2,3-二氢-6-甲基-3-氧代吡嗪-4-羧酸 | 74557-73-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 哒嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2,3-二氢-6-甲基-3-氧代吡嗪-4-羧酸
• 中文别名: 6-甲基-3-氧代-2,3-二氢哒嗪-4-羧酸
• 英文名称: 6-methyl-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid
• 英文别名: 6-Methyl-3-oxo-2,3-dihydro-pyridazin-4-carbonsaeure；6-Methyl-3-oxo-2,3-dihydropyridazine-4-carboxylic acid；3-methyl-6-oxo-1H-pyridazine-5-carboxylic acid
• CAS: 74557-73-6
• 化学式: C₆H₆N₂O₃
• mdl: MFCD08235213
• 分子量: 154.125
• InChiKey: MHYFUPKDKSSFRZ-UHFFFAOYSA-N

物化性质

• 熔点：
  130 °C
• 密度：
  1.52±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  78.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22
• 海关编码：
  2933990090
• 危险性防范说明：
  P264,P270,P301+P312+P330,P501
• 危险性描述：
  H302

反应信息

• 作为反应物：
  描述：

  2,3-二氢-6-甲基-3-氧代吡嗪-4-羧酸 生成 6-甲基-3(2H)-哒嗪酮
  参考文献：
  名称：

  杂环研究中的化学研究。10. Mitteilung。哒嗪。Zur neuen哒嗪合成。甲基哒嗪

  摘要：

  在较早的出版物中描述的新哒嗪合成中，使用甲基乙二醛作为α-二羰基组分，可以用氰基乙酸酰肼得到两个异构的甲基5-氰基-吡啶并酮-（6）。甲基的位置已被证明。

  DOI：

  10.1002/hlca.19540370514
• 作为产物：
  描述：

  ethyl 3-methyl-6-oxo-4,5-dihydro-1H-pyridazine-5-carboxylate 在 溴 作用下， 生成 2,3-二氢-6-甲基-3-氧代吡嗪-4-羧酸
  参考文献：
  名称：

  Homer et al., Journal of the Chemical Society, 1948, p. 2191,2194

  摘要：

  DOI：

文献信息

• [EN] ANTI-RSV COMPOUNDS<br/>[FR] COMPOSÉS ANTI-VRS
  申请人：GILEAD SCIENCES INC

  公开号：WO2011005842A1

  公开（公告）日：2011-01-13

  The present invention relates to anti-RSV compounds of Formula (I) and methods for use of the compounds in the treatment and prevention of RSV infection.

  本发明涉及式(I)的抗RSV化合物，以及利用这些化合物在治疗和预防RSV感染中的方法。
• HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：INFINITY PHARMACEUTICALS, INC.

  公开号：US20130267521A1

  公开（公告）日：2013-10-10

  Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

  本发明描述了调节激酶活性的化合物和药物组合物，包括PI3激酶活性，以及用于治疗与激酶活性相关的疾病和状况的化合物、药物组合物和方法，包括PI3激酶活性。
• [EN] HETEROCYCLIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS UTILISATIONS
  申请人：INFINITY PHARMACEUTICALS INC

  公开号：WO2013154878A1

  公开（公告）日：2013-10-17

  Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

  本文描述了调节激酶活性，包括PI3激酶活性的化合物和制药组合物，以及与激酶活性，包括PI3激酶活性相关的疾病和病症的治疗方法、化合物和制药组合物。
• Modulation of Amyloidogenic Protein Self-Assembly Using Tethered Small Molecules
  作者：Emma E. Cawood、Nicolas Guthertz、Jessica S. Ebo、Theodoros K. Karamanos、Sheena E. Radford、Andrew J. Wilson

  DOI：10.1021/jacs.0c10629

  日期：2020.12.9

  Protein-protein interactions (PPIs) are involved in many of life's essential biological functions yet are also an underlying cause of several human diseases, including amyloidosis. The modulation of PPIs presents opportunities to gain mechanistic insights into amyloid assembly, particularly through the use of methods which can trap specific intermediates for detailed study. Such information can also provide a starting point for drug discovery. Here, we demonstrate that covalently tethered small molecule fragments can be used to stabilize specific oligomers during amyloid fibril formation, facilitating the structural characterization of these assembly intermediates. We exemplify the power of covalent tethering using the naturally occurring truncated variant (ΔN6) of the human protein β2-microglobulin (β2m), which assembles into amyloid fibrils associated with dialysis-related amyloidosis. Using this approach, we have trapped tetramers formed by ΔN6 under conditions which would normally lead to fibril formation and found that the degree of tetramer stabilization depends on the site of the covalent tether and the nature of the protein-fragment interaction. The covalent protein-ligand linkage enabled structural characterization of these trapped, off-pathway oligomers using X-ray crystallography and NMR, providing insight into why tetramer stabilization inhibits amyloid assembly. Our findings highlight the power of "post-translational chemical modification" as a tool to study biological molecular mechanisms.
• Heterocyclic carboxylic acid amides as PDK1 inihibitors
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2560967B1

  公开（公告）日：2017-12-20